CN101528702A - 喹啉化合物和使用方法 - Google Patents

喹啉化合物和使用方法 Download PDF

Info

Publication number
CN101528702A
CN101528702A CNA2007800294412A CN200780029441A CN101528702A CN 101528702 A CN101528702 A CN 101528702A CN A2007800294412 A CNA2007800294412 A CN A2007800294412A CN 200780029441 A CN200780029441 A CN 200780029441A CN 101528702 A CN101528702 A CN 101528702A
Authority
CN
China
Prior art keywords
compound
fluorophenyls
quinoline
bases epoxide
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800294412A
Other languages
English (en)
Chinese (zh)
Inventor
J·高迪诺
S·A·博伊德
A·L·马罗
T·卡普兰
方建朝
徐廷法
田红旗
J·布莱克
K·科赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN101528702A publication Critical patent/CN101528702A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
CNA2007800294412A 2006-06-08 2007-06-08 喹啉化合物和使用方法 Pending CN101528702A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81190906P 2006-06-08 2006-06-08
US60/811,909 2006-06-08

Publications (1)

Publication Number Publication Date
CN101528702A true CN101528702A (zh) 2009-09-09

Family

ID=38658188

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800294412A Pending CN101528702A (zh) 2006-06-08 2007-06-08 喹啉化合物和使用方法

Country Status (6)

Country Link
US (1) US20110053931A1 (https=)
EP (1) EP2032538A2 (https=)
JP (1) JP2009539878A (https=)
CN (1) CN101528702A (https=)
CA (1) CA2655128A1 (https=)
WO (1) WO2007146824A2 (https=)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558147A (zh) * 2010-12-23 2012-07-11 江苏先声药物研究有限公司 化合物、制备方法及应用
CN102643268A (zh) * 2011-12-30 2012-08-22 沈阳药科大学 喹啉类及噌啉类化合物及其应用
CN103124729A (zh) * 2010-08-28 2013-05-29 利德探索中心有限公司 作为Axl抑制剂的药物活性化合物
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN103965107A (zh) * 2013-02-06 2014-08-06 沈阳药科大学 2-芳基取代喹啉类化合物及其用途
CN104072480A (zh) * 2013-03-27 2014-10-01 沈阳药科大学 喹啉类化合物及其制备方法和应用
CN104086529A (zh) * 2014-05-18 2014-10-08 马宝花 一种喹唑啉类衍生物、其制备方法及其用途
CN104817497A (zh) * 2015-03-20 2015-08-05 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN104926789A (zh) * 2015-05-20 2015-09-23 沈阳药科大学 含咪唑酮的4-苯氧基取代喹啉类化合物及其应用
CN105307656A (zh) * 2013-06-06 2016-02-03 默克专利股份公司 巨噬细胞刺激1受体mst1r的喹啉抑制剂
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
CN107474039A (zh) * 2016-06-08 2017-12-15 沈阳药科大学 含三氮唑酮和咪唑的4-苯氧基取代喹啉类化合物及其应用
CN108299292A (zh) * 2018-02-13 2018-07-20 安徽工业大学 5,7-二溴-8-(甲氧甲氧基)-2-甲基喹啉或其药用盐在治疗乳腺癌中的应用
CN108707145A (zh) * 2018-07-05 2018-10-26 沈阳药科大学 含五元杂环结构的喹啉类化合物及其制备和应用
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
WO2020042618A1 (zh) * 2018-08-27 2020-03-05 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用
WO2020118753A1 (zh) * 2018-12-12 2020-06-18 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
US10836747B2 (en) 2017-01-26 2020-11-17 Ono Pharmaceutical Co., Ltd. Ethane-sulfonate salt of quinoline derivative
CN112513030A (zh) * 2018-06-01 2021-03-16 里格尔药品股份有限公司 用作酪氨酸激酶抑制剂的喹啉衍生物
CN113302188A (zh) * 2019-01-03 2021-08-24 阵列生物制药公司 作为tam及met激酶抑制剂的喹啉化合物
RU2789405C2 (ru) * 2018-12-12 2023-02-02 Тарапьютикс Сайенс Инк. Ингибитор киназы pan-kit, имеющий структуру хинолина, и его применение
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
WO2024000615A1 (zh) * 2022-06-29 2024-01-04 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN117343046A (zh) * 2023-09-25 2024-01-05 辽宁大学 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
CN120289432A (zh) * 2025-06-12 2025-07-11 上海健康医学院 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途
US12371428B2 (en) 2019-09-26 2025-07-29 Exelixis, Inc. Pyridone compounds and methods of use

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
US7776857B2 (en) * 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
BRPI0816064B8 (pt) 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
RU2601892C2 (ru) * 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
EP2262772B8 (en) * 2008-04-16 2013-03-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as axl kinase inhibitors
US8389500B2 (en) 2008-10-30 2013-03-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
WO2012011548A1 (ja) * 2010-07-23 2012-01-26 国立大学法人 東京大学 含窒素複素環誘導体
US20140080810A1 (en) 2010-11-15 2014-03-20 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
SI2864291T1 (sl) 2012-06-26 2017-01-31 Bayer Pharma Aktiengesellschaft N-(4-(kinolin-4-iloksi)cikloheksil(metil))(hetero)arilkarboksamidi kot antagonisti receptorja androgena, njihova izdelava in uporaba kot medicinski izdelki
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
SMT201700513T1 (it) * 2013-05-01 2018-01-11 Celgene Corp Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
CN103739596A (zh) * 2013-12-10 2014-04-23 刘磊 用于心脑血管疾病的喹唑啉衍生物
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10550135B2 (en) 2016-03-30 2020-02-04 Council Of Scientific & Industrial Research Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3045224A1 (en) 2016-12-16 2018-06-21 Basf Se Pesticidal compounds
CN110506038B (zh) 2017-03-28 2023-11-24 巴斯夫欧洲公司 杀害虫化合物
CA3086083A1 (en) 2017-12-21 2019-06-27 Basf Se Pesticidal compounds
WO2019124548A1 (ja) 2017-12-22 2019-06-27 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
CN110483482A (zh) 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
WO2020027723A1 (en) * 2018-08-01 2020-02-06 Agency For Science, Technology And Research Bicyclic compounds as kinase modulators, methods and uses thereof
US20220033363A1 (en) 2018-09-19 2022-02-03 Bayer Aktiengesellschaft Herbicidally active substituted phenylpyrimidine hydrazides
EP3643705A1 (en) 2018-10-24 2020-04-29 Basf Se Pesticidal compounds
AU2020210863B2 (en) * 2019-01-25 2025-10-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
EP4011885A4 (en) * 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
IL313548A (en) 2021-12-16 2024-08-01 Kinnate Biopharma Inc MET kinase inhibitors
WO2026024165A1 (ko) * 2024-07-22 2026-01-29 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
AU2002303892A1 (en) * 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AU2002345792A1 (en) * 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
EP2258366B1 (en) * 2001-06-22 2013-04-03 Kirin Pharma Kabushiki Kaisha Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
BR0308162A (pt) * 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
US6790852B2 (en) * 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
AU2003272740A1 (en) * 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
CA2517256C (en) * 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
MXPA05013181A (es) * 2003-06-06 2006-06-23 Genentech Inc Metodos y composiciones para modular hgf/met.
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP1644362A2 (en) * 2003-07-02 2006-04-12 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
CA2536470A1 (en) * 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
EP1660504B1 (en) * 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
EP1660503A1 (en) * 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
AU2004284420A1 (en) * 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
PT2213661E (pt) * 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
JP4932495B2 (ja) * 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
WO2005073224A2 (en) * 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
EP1781293A1 (en) * 2004-06-04 2007-05-09 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
KR101257343B1 (ko) * 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
MX2007006230A (es) * 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
US20080161305A1 (en) * 2005-04-06 2008-07-03 Exelixis, Inc. C-Met Modulators and Methods of Use
US7470693B2 (en) * 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
US7732613B2 (en) * 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007035428A1 (en) * 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
BRPI0708615A2 (pt) * 2006-03-07 2011-06-07 Array Biopharma Inc compostos de pirazol heterobicìclicos e métodos de uso
DK2124944T3 (da) * 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
CN101918403A (zh) * 2007-09-06 2010-12-15 阵列生物制药公司 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103124729B (zh) * 2010-08-28 2016-01-20 利德探索中心有限公司 作为Axl抑制剂的药物活性化合物
CN103124729A (zh) * 2010-08-28 2013-05-29 利德探索中心有限公司 作为Axl抑制剂的药物活性化合物
CN102558147B (zh) * 2010-12-23 2014-09-17 江苏先声药物研究有限公司 化合物、制备方法及应用
CN102558147A (zh) * 2010-12-23 2012-07-11 江苏先声药物研究有限公司 化合物、制备方法及应用
US10017496B2 (en) 2011-11-14 2018-07-10 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN108047201A (zh) * 2011-11-14 2018-05-18 亚尼塔公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
US9745283B2 (en) 2011-11-14 2017-08-29 Ignyta, Inc. Uracil derivatives as AXL and c-MET kinase inhibitors
CN102643268A (zh) * 2011-12-30 2012-08-22 沈阳药科大学 喹啉类及噌啉类化合物及其应用
CN103965107A (zh) * 2013-02-06 2014-08-06 沈阳药科大学 2-芳基取代喹啉类化合物及其用途
CN103965107B (zh) * 2013-02-06 2016-08-17 沈阳药科大学 2-芳基取代喹啉类化合物及其用途
CN104072480A (zh) * 2013-03-27 2014-10-01 沈阳药科大学 喹啉类化合物及其制备方法和应用
CN104072480B (zh) * 2013-03-27 2016-12-28 沈阳药科大学 喹啉类化合物及其制备方法和应用
CN105307656B (zh) * 2013-06-06 2019-02-19 利德发现中心有限责任公司 巨噬细胞刺激1受体mst1r的喹啉抑制剂
CN105307656A (zh) * 2013-06-06 2016-02-03 默克专利股份公司 巨噬细胞刺激1受体mst1r的喹啉抑制剂
CN105408312B (zh) * 2013-07-24 2018-09-25 小野药品工业株式会社 喹啉衍生物
US10676462B2 (en) 2013-07-24 2020-06-09 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
US10501442B2 (en) 2013-07-24 2019-12-10 Ono Pharmaceuticals Co., Ltd. Quinoline derivative
US10208022B2 (en) 2013-07-24 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
US9994549B2 (en) 2013-07-24 2018-06-12 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN104086529A (zh) * 2014-05-18 2014-10-08 马宝花 一种喹唑啉类衍生物、其制备方法及其用途
CN104086529B (zh) * 2014-05-18 2015-12-30 马宝花 一种喹唑啉类衍生物、其制备方法及其用途
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
CN104817497A (zh) * 2015-03-20 2015-08-05 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN104926789A (zh) * 2015-05-20 2015-09-23 沈阳药科大学 含咪唑酮的4-苯氧基取代喹啉类化合物及其应用
CN107474039B (zh) * 2016-06-08 2020-05-01 沈阳药科大学 含三氮唑酮和咪唑的4-苯氧基取代喹啉类化合物及其应用
CN107474039A (zh) * 2016-06-08 2017-12-15 沈阳药科大学 含三氮唑酮和咪唑的4-苯氧基取代喹啉类化合物及其应用
US10836747B2 (en) 2017-01-26 2020-11-17 Ono Pharmaceutical Co., Ltd. Ethane-sulfonate salt of quinoline derivative
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN108299292A (zh) * 2018-02-13 2018-07-20 安徽工业大学 5,7-二溴-8-(甲氧甲氧基)-2-甲基喹啉或其药用盐在治疗乳腺癌中的应用
CN108299292B (zh) * 2018-02-13 2021-03-26 安徽工业大学 5,7-二溴-8-(甲氧甲氧基)-2-甲基喹啉或其药用盐在治疗乳腺癌中的应用
CN112513030A (zh) * 2018-06-01 2021-03-16 里格尔药品股份有限公司 用作酪氨酸激酶抑制剂的喹啉衍生物
CN108707145A (zh) * 2018-07-05 2018-10-26 沈阳药科大学 含五元杂环结构的喹啉类化合物及其制备和应用
CN108707145B (zh) * 2018-07-05 2021-02-26 沈阳药科大学 含五元杂环结构的喹啉类化合物及其制备和应用
CN113195471B (zh) * 2018-08-27 2023-05-02 苏州浦合医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用
WO2020042618A1 (zh) * 2018-08-27 2020-03-05 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用
CN113195471A (zh) * 2018-08-27 2021-07-30 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用
WO2020118753A1 (zh) * 2018-12-12 2020-06-18 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
RU2789405C2 (ru) * 2018-12-12 2023-02-02 Тарапьютикс Сайенс Инк. Ингибитор киназы pan-kit, имеющий структуру хинолина, и его применение
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
CN111303024A (zh) * 2018-12-12 2020-06-19 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
US12404244B2 (en) 2018-12-12 2025-09-02 Tarapeutics Science Inc. Pan-KIT kinase inhibitor having quinoline structure and application thereof
CN113302188A (zh) * 2019-01-03 2021-08-24 阵列生物制药公司 作为tam及met激酶抑制剂的喹啉化合物
US12371428B2 (en) 2019-09-26 2025-07-29 Exelixis, Inc. Pyridone compounds and methods of use
WO2024000615A1 (zh) * 2022-06-29 2024-01-04 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN117343046A (zh) * 2023-09-25 2024-01-05 辽宁大学 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
CN120289432A (zh) * 2025-06-12 2025-07-11 上海健康医学院 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途
CN120289432B (zh) * 2025-06-12 2025-09-05 上海健康医学院 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途

Also Published As

Publication number Publication date
EP2032538A2 (en) 2009-03-11
WO2007146824A3 (en) 2008-04-10
US20110053931A1 (en) 2011-03-03
JP2009539878A (ja) 2009-11-19
CA2655128A1 (en) 2007-12-21
WO2007146824A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
CN101528702A (zh) 喹啉化合物和使用方法
US8003662B2 (en) Heterobicyclic thiophene compounds and methods of use
US7723330B2 (en) Heterobicyclic pyrazole compounds and methods of use
CN102459187B (zh) Janus激酶抑制化合物和方法
CN110573500B (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
RU2592703C2 (ru) ИНГИБИТОРЫ ТИПА ErbB
US20110130406A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
TW202039490A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
JP2022530097A (ja) がんを処置するためのアシルスルホンアミド類
AU2011311814B2 (en) Substituted pyridazine carboxamide compounds
TW200848414A (en) Organic compounds and their uses
KR20130115997A (ko) 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
CN103539780A (zh) 取代的吡唑酮化合物及其使用方法和用途
CN101437820A (zh) 杂二环吡唑化合物和使用方法
WO2014180182A1 (zh) [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用
WO2025051157A1 (zh) 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
CN114555597A (zh) 异柠檬酸脱氢酶（idh）抑制剂
WO2025026195A1 (zh) 取代的含氮双环化合物及其用途
HK40088834B (zh) 杂芳环氮氧化合物及其制备方法和应用
HK40088834A (zh) 杂芳环氮氧化合物及其制备方法和应用
HK40115331A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
HK40004229A (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2014154026A1 (zh) PI3K和/或mTOR抑制剂的前药

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090909